Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Ann Intern Med. 2009 Nov 17;151(10):738-47. doi: 10.7326/0003-4819-151-10-200911170-00010.

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Author information

  • 1Georgetown University Medical Center and Lombardi Comprehensive Cancer Center, Washington, DC, USA. mandelbj@georgetown.edu

Erratum in

  • Ann Intern Med. 2010 Jan 19;152(2):136.

Abstract

BACKGROUND:

Despite trials of mammography and widespread use, optimal screening policy is controversial.

OBJECTIVE:

To evaluate U.S. breast cancer screening strategies.

DESIGN:

6 models using common data elements.

DATA SOURCES:

National data on age-specific incidence, competing mortality, mammography characteristics, and treatment effects.

TARGET POPULATION:

A contemporary population cohort.

TIME HORIZON:

Lifetime.

PERSPECTIVE:

Societal.

INTERVENTIONS:

20 screening strategies with varying initiation and cessation ages applied annually or biennially.

OUTCOME MEASURES:

Number of mammograms, reduction in deaths from breast cancer or life-years gained (vs. no screening), false-positive results, unnecessary biopsies, and overdiagnosis.

RESULTS OF BASE-CASE ANALYSIS:

The 6 models produced consistent rankings of screening strategies. Screening biennially maintained an average of 81% (range across strategies and models, 67% to 99%) of the benefit of annual screening with almost half the number of false-positive results. Screening biennially from ages 50 to 69 years achieved a median 16.5% (range, 15% to 23%) reduction in breast cancer deaths versus no screening. Initiating biennial screening at age 40 years (vs. 50 years) reduced mortality by an additional 3% (range, 1% to 6%), consumed more resources, and yielded more false-positive results. Biennial screening after age 69 years yielded some additional mortality reduction in all models, but overdiagnosis increased most substantially at older ages.

RESULTS OF SENSITIVITY ANALYSIS:

Varying test sensitivity or treatment patterns did not change conclusions.

LIMITATION:

Results do not include morbidity from false-positive results, patient knowledge of earlier diagnosis, or unnecessary treatment.

CONCLUSION:

Biennial screening achieves most of the benefit of annual screening with less harm. Decisions about the best strategy depend on program and individual objectives and the weight placed on benefits, harms, and resource considerations. Primary Funding Source: National Cancer Institute.

PMID:
19920274
[PubMed - indexed for MEDLINE]
PMCID:
PMC3515682
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Appendix Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Write to the Help Desk